People: Sequenom Inc (SQNM.OQ)

SQNM.OQ on NASDAQ Stock Exchange Global Select Market

2.59USD
17 Apr 2014
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.59
Open
$2.58
Day's High
$2.66
Day's Low
$2.51
Volume
328,713
Avg. Vol
373,607
52-wk High
$4.89
52-wk Low
$1.65

Search Stocks

Summary

Name Age Since Current Position

Harry Hixson

74 2009 Chairman of the Board, Chief Executive Officer

Paul Maier

65 2009 Chief Financial Officer

William Welch

52 2012 President, Chief Operating Officer

R. William Bowen

60 2012 Senior Vice President, General Counsel, Secretary

Michael Monko

53 2011 Senior Vice President - Genetic Analysis

Robin Weiner

57 2010 Senior Vice President - Quality and Regulatory Affairs

Dirk van den Boom

43 2012 Executive Vice President - Research and Development, Chief Technology Officer

Carolyn Beaver

56 2012 Vice President, Chief Accounting Officer

Charles Cantor

70 2010 Chief Scientific Officer

Alisa Judge

57 2007 Vice President - Human Resources

Allan Bombard

60 2009 Chief Medical Officer

Richard Lerner

75 2010 Lead Independent Director

Myla Lai-Goldman

56 2012 Director

Ronald Lindsay

65 2013 Director

Ernst-Gunter Afting

71 1996 Independent Director

Kenneth Buechler

59 2009 Independent Director

John Fazio

69 2007 Independent Director

David Pendarvis

54 2009 Independent Director

Charles Slacik

58 2011 Independent Director

Donna Nichols

2013 IR Contact Officer

Biographies

Name Description

Harry Hixson

Dr. Harry F. Hixson, Jr., Ph.D., is Chairman of the Board of Sequenom Inc. Dr. Hixson is no longer Chief Executive Officer of the Company, effective June 10, 2014. He served as a director of BrainCells, Inc., from December 2003 to February 2011, where he also served as Chief Executive Officer from July 2004 until September 2005. Dr. Hixson served as Chief Executive Officer of Elitra Pharmaceuticals, Inc., a biopharmaceutical company focused on anti-infective drug development, from February 1998 until May 2003. He served as President and Chief Operating Officer of Amgen Inc., and as a member of its board of directors from 1988 to 1991. Prior to Amgen, Dr. Hixson held various management positions with Abbott Laboratories, including Vice President, Diagnostic Products Business Group, and Vice President, Research and Development, in the Diagnostics Division. Dr. Hixson also is a director of Arena Pharmaceuticals, Inc., and from September 2006 until May 2010 served as a director of Infinity Pharmaceuticals, Inc., and from February 2009 until September 2010 served as a director of Novabay Pharmaceuticals. Dr. Hixson received his Ph.D. in Physical Biochemistry from Purdue University and an M.B.A. from the University of Chicago.

Paul Maier

Mr. Paul V. Maier, M.B.A., is no longer Chief Financial Officer of Sequenom Inc., effective June 10, 2014. Mr. Maier served as senior vice president and chief financial officer of Ligand Pharmaceuticals Incorporated from 1992 until January 2007, where he helped build Ligand from a venture stage company to a commercial, integrated biopharmaceutical organization. Prior to Ligand, Mr. Maier spent six years in various management and finance positions at ICN Pharmaceuticals. Mr. Maier currently serves as a director of Talon Therapeutics (formerly Hana Biosciences, Inc.), Pure Bioscience, and International Stem Cell Corporation. Mr. Maier received his M.B.A. from Harvard University.

William Welch

Mr. William J. Welch has been President, Chief Executive Officer, Chief Operating Officer of Sequenom Inc. He has been appointed as Chief Executive Officer of the Company, effective June 10, 2014. He had previously served as senior vice president, diagnostics. Prior to joining, Mr. Welch was a consultant to molecular diagnostic companies in the personalized medicine sector. From August 2005 to September 2009, Mr. Welch was senior vice president and chief commercial officer at Monogram Biosciences, a bioscience laboratory services company. Prior to Monogram, Mr. Welch was vice president of sales and marketing at La Jolla Pharmaceuticals and vice president of global marketing with Dade Behring MicroScan. Mr. Welch entered the healthcare field with Abbott Laboratories where he held progressive management positions, including General Manager. Mr. Welch holds a B.S. with honors in chemical engineering from the University of California at Berkeley and received his M.B.A. from Harvard University.

R. William Bowen

Mr. William Bowen is Senior Vice President, General Counsel, Secretary of Sequenom Inc,. Mr. Bowen previously served as Senior Vice President, General Counsel and Secretary of Gen-Probe Incorporated, a molecular diagnostic company focused on infectious disease, from June 1997 to August 2012. Prior to Gen-Probe, Mr. Bowen was a business litigation partner with the law firm of Luce, Forward, Hamilton & Scripps in San Diego, California. Mr. Bowen received a J.D. and a B.S. in commerce from the University of Virginia.

Michael Monko

Mr. Michael Monko, M.B.A., is Senior Vice President - Genetic Analysis of Sequenom Inc. He previously served as the company's senior vice president, sales and marketing since August 2006. Mr. Monko served as vice president of sales for the organization that is now the diagnostics strategic business unit of Millipore, a bioscience research and biopharmaceutical manufacturing supplier, from 2005 to July 2006. Previously, he served 19 years in various sales roles at Invitrogen Corporation (now Life Technologies, Corp.), a biotechnology tools company. Mr. Monko received his M.B.A. from Babson College.

Robin Weiner

Ms. Robin G. Weiner, MBA., serves as Senior Vice President - Quality and Regulatory Affairs of Sequenom Inc. Prior to joining the company, Ms. Weiner was an independent regulatory consultant to biotechnology companies, focusing on regulatory strategy, product submissions and quality management systems. From 2004 to 2007, Ms. Weiner served as vice president regulatory and government affairs at Biosite Incorporated, a medical device company, and was responsible for Biosite’s worldwide product approvals and regulatory compliance activities. Ms. Weiner holds a bachelor’s degree from the University of California, San Diego and a master’s degree in business administration from National University.

Dirk van den Boom

Dr. Dirk van den Boom, Ph.D., has been appointed as Chief Scientific & Strategy Officer of the Company, effective June 10, 2014. Dr. van den Boom has served as Sequenom's Senior Vice President of research and development since August 2010 and previously served as the Company's vice president, research and development. He joined Sequenom in 1998 at the company's Hamburg office, subsequently serving in various management roles of increasing responsibility within the R&D department. Dr. van den Boom received his Ph.D. in Biochemistry/Molecular Biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry. He has co-authored more than 50 scientific articles and is an inventor on 48 patents or patent applications.

Carolyn Beaver

Ms. Carolyn Beaver has been Vice Chief Financial Officer, Chief Accounting Officer, Vice President of Sequenom Inc. She has been appointed as Chief Financial Officer effective June 10, 2014. Since its acquisition by Danaher Corp. in June 2011, Ms. Beaver has continued to serve at Beckman Coulter, Inc. as the Corporate Vice President, Controller. From 1987 until 2002, Ms. Beaver was a partner with KPMG LLP. Ms. Beaver also currently serves as a director of Commerce National Bank, a position she has held since 2005. Ms. Beaver holds a B.S. in Accounting from California State Polytechnic University, Pomona.

Charles Cantor

Dr. Charles R. Cantor, Ph.D., is Chief Scientific Officer of Sequenom Inc. He served as a member of the board of directors from 1998 to 2010. From 1992 to 2011, Dr. Cantor served as a professor in the Department of Biomedical Engineering and co-director of the Center for Advanced Biotechnology at Boston University and he is now professor emeritus. Prior to that time, Dr. Cantor held positions at Columbia University and the University of California, Berkeley. He was also director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. Dr. Cantor published the first textbook on genomics, The Science and Technology of the Human Genome Project. Dr. Cantor is a member of the National Academy of Sciences. He is also a scientific advisor to 12 biotechnology and life science companies and one venture capital firm. Dr. Cantor currently serves as a director of ExSAR, Inc., Human BioMolecular Research Institute, DiThera, Inc., a biotechnology company that he founded in 2007, and Retrotrope, Inc. a biotechnology company that he founded in 2007. Dr. Cantor received his Ph.D. in Chemistry from the University of California, Berkeley.

Alisa Judge

Ms. Alisa Judge serves as Vice President - Human Resources of Sequenom Inc. She brings over 20 years of human resources experience having previously served as vice president of human resources, from April 2005 to June 2007, at Claritas, a division of the Nielsen Company, a provider of marketing information and audience measurement. Prior to Claritas, from February 2003 to February 2005, Ms. Judge held the same role for GKN Aerospace Chem-tronics, a supplier to automotive and aerospace manufacturers. Ms. Judge holds a B.S. in Business from Humboldt State University.

Allan Bombard

Dr. Allan T. Bombard, M.D., M.B.A, is Chief Medical Officer of Sequenom Inc. He also served as CLIA/CAP Laboratory Director since June 2010. From October 2008 to January 2009, Dr. Bombard was the chief executive officer of Lenetix Medical Laboratory, which provided genetic screening and diagnostic testing for obstetricians, gynecologists, family practitioners, nurse midwives, laboratories, diagnostic facilities and other healthcare providers. From April 2005 to October 2008, Dr. Bombard was chief medical officer of Sharp Mary Birch Hospital for Women. From 2002 to 2005, Dr. Bombard served as senior vice president, chair, and residency program director of the Department of Obstetrics and Gynecology at Lutheran Medical Center. Prior to Lutheran Medical Center, he served as the western United States medical director for women’s health at Aetna. Dr. Bombard is currently clinical professor in the Department of Reproductive Medicine at the University of California San Diego. Dr. Bombard received his M.D. from the George Washington University and his M.B.A. from the University of San Diego.

Richard Lerner

Professor Dr. Richard A. Lerner, M.D., serves as Lead Independent Director of Sequenom Inc.Dr. Lerner served as President of the Scripps Research Institute, a private, non-profit biomedical research organization from 1986 to January 2012, and since then has served and continues to serve as Institute Professor. Dr. Lerner received the Wolf Prize in Chemistry in 1994, the California Scientist of the Year Award in 1996, the Paul Ehrlich and Ludwig Darmstaedter Prize in 2003, and the Prince of Asturias Award in 2012 for his achievements in the development of catalytic antibodies and combinatorial antibody libraries. Dr. Lerner is a member of the Royal Swedish Academy of Sciences and the National Academy of Sciences. Dr. Lerner served as a director of Kraft Foods, Inc. from 2005 to March 2012 and currently serves as a director of Opko Health, Inc., Teva Pharmaceutical Industries Ltd., and IntraCellular Therapies. Dr. Lerner received his M.D. from Stanford Medical School.

Myla Lai-Goldman

Dr. Myla P. Lai-Goldman, M.D., has been appointed as Director of Sequenom, Inc., effective September 11, 2012. Since September 2008, she has been the managing partner of Personalized Science, LLC, a consulting company she founded that is focused on innovative diagnostics for patients’ unmet clinical needs. Dr. Lai-Goldman is also the Chief Executive Officer and President of GeneCentric Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing assays that enable oncologists and their patients to make informed, individualized, treatment decisions. Dr. Lai-Goldman has been with GeneCentric Diagnostics, Inc., since June 2011. Dr. Lai-Goldman is also a venture partner with Hatteras Venture Partners, as position she has held since August 2011. From June 2009 to December 2010, Dr. Lai-Goldman was Chief Executive Officer and Chief Scientific Officer of CancerGuide Diagnostics, Inc., a life science company focused on the development and commercialization of genomic-based clinical and pharmaceutical cancer tests and services. From 1990 to December 2008, Dr. Lai-Goldman served in various roles at Laboratory Corporation of America Holdings and its predecessor company, Roche Biomedical Laboratories, a clinical laboratory company, including Executive Vice President, Chief Medical Officer, and Chief Scientific Officer. Dr. Lai-Goldman is a recognized author and speaker on clinical diagnostics. Dr. Lai-Goldman received her B.S. in biology from the University of Pennsylvania and her medical degree from Columbia University. Dr. Lai-Goldman completed a pathology residency and surgical pathology fellowship at The University of California, Los Angeles, and a hematopathology fellowship at The University of North Carolina, Chapel Hill. Dr. Lai-Goldman is board certified in anatomic and clinical pathology.

Ronald Lindsay

Dr. Ronald M. Lindsay, Ph.D., is Director of Sequenom Inc. He is no longer Executive Vice President - Strategic Planning of the Company effective December 31, 2013. He previously served as interim Senior Vice President of Research and Development from September 2009 until August 2010. Dr. Lindsay has served as a member of Board of Directors since 2003. He currently operates Milestone Consulting, a biopharmaceutical consulting firm. Dr. Lindsay served as Vice President, Research and Development, and Chief Science Officer of diaDexus Inc., a biotechnology company, from 2000 to January 2004. From 1997 through 2000, Dr. Lindsay served in various senior management roles with Millennium Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 to 1997, Dr. Lindsay served in various roles with Regeneron Pharmaceuticals Inc., of which he was a founding scientist. He is a director of Arqule Inc., and HistoRx Inc. Dr. Lindsay received his Ph.D. in Biochemistry from the University of Calgary.

Ernst-Gunter Afting

Dr. Ernst-Gunter Afting, Ph.D., M.D., is no longer Independent Director of Sequenom Inc., effective June 10, 2014. From 1995 until his retirement in 2006, Dr. Afting served as President and Chief Executive Officer of the National Research Center for Environment and Health, GSF-National Research Center for Environment and Health GmbH, a governmental research center in Munich, Germany. From 1993 to 1995, he served as President and Chief Executive Officer of Roussel UCLAF, Paris, a pharmaceutical company. He was also a member of the board of directors of the Pharmaceutical Division of Hoechst Group from 1984 to 1993 and was chairman and Chief Executive Officer of the Divisional Pharmaceutical Board of Hoechst from 1992 to 1993. Dr. Afting was a member of the Advisory Committee on Science and Technology to German Chancellor Helmut Kohl from 1996 to 1997 and from 1996 to 2005 was a member of the German National Advisory Committee on Health Research to the State Secretaries of Science, Technology and Health. Dr. Afting has been a member of the medical faculty at the University of Goettingen since 1985. Dr. Afting currently serves on the boards of Intercell AG, Enanta Pharmaceuticals, Inc., and Olympus Europa GmbH. He received his Ph.D. in Chemistry and M.D. from the University of Freiburg/Breisgau, Germany.

Kenneth Buechler

Dr. Kenneth F. Buechler, Ph.D., serves as an Independent Director of Sequenom Inc., since December 2009. Dr. Buechler was President and Chief Scientific Officer of Biosite Incorporated, a provider of diagnostic products and antibody development technologies, from 2003 to 2007, and prior to that was a co-founder and held roles as Director of Chemistry and Vice-President of Research and Development from 1988 to 2003. Prior to forming Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated, a biotechnology company located in San Diego. Dr. Buechler served on the board of directors of Adnavance, Inc. from March 2008 until April 2010. Dr. Buechler currently serves on the board of directors of Quidel Corp., Sotera Wireless Inc., and Astute Medical Inc. Dr. Buechler received his Ph.D in biochemistry from Indiana University.

John Fazio

Mr. John A. Fazio serves as an Independent Director of Sequenom Inc., since 2007. Mr. Fazio is a former senior general practice partner of PricewaterhouseCoopers, a global accounting and professional services company. Mr. Fazio retired from PricewaterhouseCoopers in 2000 following 35 years of service during which he held a variety of senior positions in accounting, auditing, consulting, and administration. Currently, Mr. Fazio serves on the board of directors of Heidrick & Struggles International, Inc. Mr. Fazio served on the board of directors of Imclone Systems, Inc. from February 2003 until April 2006, and served on the board of directors of Dendrite International, Inc. from March 2003 until August 2007. Mr. Fazio is a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants and holds an M.A. from Ohio State University.

David Pendarvis

Mr. David Pendarvis serves as an Independent Director of Sequenom Inc., since December 2009. Mr. Pendarvis is Chief Administrative Officer, Global General Counsel and Secretary of ResMed Inc., a medical device company focused on sleep-disordered breathing. He has been with ResMed since 2002. From 2000 until 2002, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP. Until 2000 he was a partner with Gibson, Dunn & Crutcher LLP, where he began working in 1986. From 1984 until 1986 he was a law clerk to the Hon. J. Lawrence Irving, US District Judge, Southern District of California. Mr. Pendarvis received his J.D. from the University of Texas School of Law and his M.S. in executive leadership from the University of San Diego.

Charles Slacik

Mr. Charles P. Slacik serves as an Independent Director of Sequenom Inc., since June 15, 2011. Mr. Slacik was Chief Financial Officer and Senior Vice President of Finance of Beckman Coulter Inc., a leading manufacturer of biomedical testing instrument systems, tests and supplies, from October 2006 to September 2011 and was responsible for all aspects of financial management and information technology. From 2003 to 2006, Mr. Slacik served as Executive Vice President and Chief Financial Officer of Watson Pharmaceuticals, Inc., an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, brand and biologic pharmaceutical products. From 1999 to 2003, Mr. Slacik served as Senior Vice President and Chief Financial officer of C.R. Bard, Inc., a developer and manufacturer of medical technologies in the fields of vascular, urology, oncology and surgical specialty products. Currently, Mr. Slacik serves on the board of directors of STAAR Surgical Company. Mr. Slacik earned a Bachelor of Science degree in accounting and finance from the University of Connecticut and is a Certified Public Accountant.

Donna Nichols

Search Stocks